Health Canada Approves IMBRUVICA? by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia

Ontario patients living with CLL and SLL who are eligible will now have access to IMBRUVICA® under the Exceptional Access Program of the Ontario Drug Benefit Program.

Eligibility criteria include those patients who:

  • have CLL/SLL and have received at least one prior therapy to treat CLL/SLL; and,
  • are inappropriate for treatment or retreatment with a fludarabine-based regimen.

To determine whether patients qualify for IMBRUVICA® treatment and for the Ontario Drug Benefit Program, patients should speak with their healthcare team.

The YOU&i™ Support Program provides no cost, personalized support services to IMBRUVICA® patients and their physicians, and offers customized advice, education and encouragement from Oncology Nurse Coaches. Visit for more information. Patients should speak with their healthcare team to enroll.

IMBRUVICA® was approved by Health Canada in November 2014 for the treatment of people with the blood cancer chronic lymphocytic leukemia (CLL), including those with 17p deletion, who have received at least one prior therapy, or for the frontline treatment of patients with CLL with 17p deletion. Press Release